Tissue inhibitor of metalloproteinase-4 is elevated in early-stage breast cancers with accelerated progression and poor clinical course

American Journal of Pathology

Volumn 175, Issue 3, 2009, Pages 940-946

  Liss, Michaelann ^a   Sreedhar, Nandhini ^a   Keshgegian, Albert ^a   Sauter, Guido ^b   Chernick, Michael R ^c   Prendergast, George C ^a,c   Wallon, U Margaretha ^c  

^a LANKENAU HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 4;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GROWTH; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DISEASE SEVERITY; EARLY CANCER; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 70349235433     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2009.081094     Document Type: Article

References (30)

1. Brew K, Dinakarpandian D, Nagase H: Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta 2000, 1477:267-283 (Pubitemid 30119906)
2. Lambert E, Dasse E, Haye B, Petitfrere E: TIMPs as multifacial proteins. Crit Rev Oncol Hematol 2004, 49:187-198
3. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP: Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 1997, 74:111-122 (Pubitemid 27455388)
4. Hojilla CV, Mohammed FF, Khokha R: Matrix metalloproteinases and their tissue inhibitors direct cell fate during cancer development. Br J Cancer 2003, 89:1817-1821 (Pubitemid 37533251)
5. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET, Malyankar UM: Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 1993, 59:329-341 (Pubitemid 23344435)
6. Koop S, Khokha R, Schmidt EE, MacDonald IC, Morris VL, Chambers AF, Groom AC: Overexpression of metalloproteinase inhibitor in B16F10 cells does not affect extravasation but reduces tumor growth. Cancer Res 1994, 54:4791-4797 (Pubitemid 24276514)
7. Murphy AN, Unsworth EJ, Stetler-Stevenson WG: Tissue inhibitor of metalloproteinases-2 inhibits bFGF-induced human microvascular endothelial cell proliferation. J Cell Physiol 1993, 157:351-358 (Pubitemid 23332780)
8. Bond M, Murphy G, Bennett MR, Amour A, Knauper V, Newby AC, Baker AH: Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus: metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem 2000, 275:41358-41363 (Pubitemid 32054970)
9. Fata JE, Leco KJ, Moorehead RA, Martin DC, Khokha R: Timp-1 is important for epithelial proliferation and branching morphogenesis during mouse mammary development. Dev Biol 1999, 211:238-254
10. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A, Anand-Apte B: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 2003, 9:407-415 (Pubitemid 36460074)
11. Khokha R, Zimmer MJ, Graham CH, Lala PK, Waterhouse P: Suppression of invasion by inducible expression of tissue inhibitor of metalloproteinase-1 (TIMP-1) in B16-F10 melanoma cells. J Natl Cancer Inst 1992, 84:1017-1022
12. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516 (Pubitemid 33096184)
13. Wang M, Liu YE, Greene J, Sheng S, Fuchs A, Rosen EM, Shi YE: Inhibition of tumor growth and metastasis of human breast cancer cells transfected with tissue inhibitor of metalloproteinase 4. Oncogene 1997, 14:2767-2774 (Pubitemid 27313408)
14. Jiang Y, Wang M, Celiker MY, Liu YE, Sang QX, Goldberg ID, Shi YE: Stimulation of mammary tumorigenesis by systemic tissue inhibitor of matrix metalloproteinase 4 gene delivery. Cancer Res 2001, 61:2365-2370 (Pubitemid 32685806)
15. Zhao YG, Xiao AZ, Park HI, Newcomer RG, Yan M, Man YG, Heffelfinger SC, Sang QX: Endometase/matrilysin-2 in human breast ductal carcinoma in situ and its inhibition by tissue inhibitors of metalloproteinases-2 and -4: a putative role in the initiation of breast cancer invasion. Cancer Res 2004, 64:590-598 (Pubitemid 38120898)
16. Hess KR, Pusztai L, Buzdar AU, Hortobagyi GN: Estrogen receptors and distinct patterns of breast cancer relapse. Breast Cancer Res Treat 2003, 78:105-118 (Pubitemid 36223023)
17. Kiba T, Inamoto T, Nishimura T, Ueno M, Yanagihara K, Teramukai S, Kato H, Toi M, Fukushima M: The reversal of recurrence hazard rate between ER positive and negative breast cancer patients with axillary lymph node dissection (pathological stage I-III) 3 years after surgery. BMC Cancer 2008, 8:323
18. Peralta Soler A, Knudsen KA, Salazar H, Han AC, Keshgegian AA: P-cadherin expression in breast carcinoma indicates poor survival. Cancer 1999, 86:1263-1272 (Pubitemid 29447011)
19. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998, 11:155-168 (Pubitemid 28144151)
20. Chernick MR, Friis RH (Eds): Introductory Biostatistics for the Health Sciences: Modern Applications Including Bootstrap. New York, John Wiley and Sons, Inc., 2003
21. Lachin JM: Biostatistical Methods: The Assessment of Relative Risk. New York, John Wiley and Sons, Inc., 2000
22. Hayes DF, Isaacs C, Stearns V: Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001, 6:375-392 (Pubitemid 39600496)
23. Kalbfleisch JD Prentice RL (Eds): The Statistical Analysis of Failure Time Data. New York, John Wiley and Sons, Inc., 2002
24. Therneau TM, Grambsch PM: Modeling Survival Data: Extending the Cox Model. New York, Springer Verlag, Inc., 2000
25. Hilska M, Roberts PJ, Collan YU, Laine VJ, Kossi J, Hirsimaki P, Rahkonen O, Laato M: Prognostic significance of matrix metalloproteinases-1, -2, -7 and -13 and tissue inhibitors of metalloproteinases-1, -2, -3 and -4 in colorectal cancer. Int J Cancer 2007, 121:714-723
26. Liu XW, Taube ME, Jung KK, Dong Z, Lee YJ, Roshy S, Sloane BF, Fridman R, Kim HR: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. Cancer Res 2005, 65:898-906 (Pubitemid 40216449)
27. Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG, Brunner N, Foekens JA: Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res 2004, 10:2289-2298 (Pubitemid 38445686)
28. Schrohl AS, Meijer-van Gelder ME, Holten-Andersen MN, Christensen IJ, Look MP, Mouridsen HT, Brunner N, Foekens JA: Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res 2006, 12:7054-7058 (Pubitemid 44974503)
29. Cleator S, Heller W, Coombes RC: Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007, 8:235-244 (Pubitemid 46291713)
30. Reis-Filho JS, Tutt AN: Triple negative tumours: a critical review. Histopathology 2008, 52:108-118